Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

8.3K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.3K
Structure and Function of Platelets01:18

Structure and Function of Platelets

2.6K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
2.6K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

928
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
928
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

8.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Micro-Nanoplastics Significantly Increase Adverse Events and Economic Burden Associated With Carotid Endarterectomy: A Health Economic Modelling Evaluation.

ANZ journal of surgery·2026
Same author

Nutrition provision across acute hospitalization in adult patients receiving extracorporeal membrane oxygenation: A prospective multicenter observational, registry-embedded study.

Nutrition (Burbank, Los Angeles County, Calif.)·2026
Same author

Comparison of Left Ventricular Pressure-Volume Loops With Veno-Arterial Extracorporeal Membrane Oxygenator Support: In Vitro Investigation.

Artificial organs·2026
Same author

Correction: Neurological manifestations of SARS-CoV-2 infection: protocol for a sub-analysis of the COVID-19 critical care consortium observational study.

Frontiers in medicine·2026
Same author

Cardiac surgery modulates leucocyte subsets and inflammatory mediators.

Immunology letters·2026
Same author

Impact of Systemic Vessel Resistance and Microaxial Pump Flow Level on Left Ventricular Workload.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same journal

Large-Eddy Simulation of the FDA Benchmark Blood Pump: Validation Against Experiments and Implications for Turbulent Flow Mechanisms.

Artificial organs·2026
Same journal

The Warm Revolution: A Meta-Analysis of DCD Versus DBD Liver Transplant Outcomes in the Normothermic Machine Perfusion Era.

Artificial organs·2026
Same journal

Toward Optimal Remote Monitoring in LVAD Recipients: Remaining Challenges Beyond Feasibility.

Artificial organs·2026
Same journal

Advancing Organ Preservation and Perfusion: Introducing the International Society of Organ Preservation and Perfusion Therapy (ISOPPT).

Artificial organs·2026
Same journal

Short Inter-Treatment Interval Treatment With Artificial Liver Support System Reduces 90-Day Transplant-Free Mortality in Patients With Hepatitis B Virus-Related Acute-On-Chronic Liver Failure: A Retrospective Observational Study.

Artificial organs·2026
Same journal

Extracorporeal Albumin Dialysis (OPAL) as Novel Therapeutic Bridging Option in Posthepatectomy Liver Failure.

Artificial organs·2026
See all related articles

Related Experiment Video

Updated: Dec 13, 2025

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
10:10

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

18.5K

Shear-dependent platelet aggregation size.

Chris Hoi Houng Chan1,2,3, Masataka Inoue1,2,4, Katrina K Ki2,3

  • 1School of Engineering and Built Environment, Griffith University, Gold Coast, QLD, Australia.

Artificial Organs
|August 1, 2020
PubMed
Summary
This summary is machine-generated.

High shear rates in left ventricular assist devices (LVADs) impair platelet aggregation, increasing bleeding risk. Maintaining shear rates below 6000 s⁻¹ is crucial for optimal platelet plug formation and reducing bleeding complications.

Keywords:
ADAMTS13exposure timeplatelet aggregateshear ratevon Willebrand factor

More Related Videos

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
04:32

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

8.1K
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

12.3K

Related Experiment Videos

Last Updated: Dec 13, 2025

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
10:10

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

18.5K
A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
04:32

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

8.1K
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

12.3K

Area of Science:

  • Biomedical Engineering
  • Hematology
  • Cardiovascular Science

Background:

  • Nonsurgical bleeding is a frequent complication in patients with left ventricular assist devices (LVADs).
  • Supraphysiologic shear rates generated by LVADs can impair platelet aggregation, elevating bleeding risk.
  • The impact of shear rate on platelet aggregate size, a critical factor in bleeding, remains understudied.

Purpose of the Study:

  • To investigate the effect of varying shear rates and exposure times on platelet aggregate formation size.
  • To determine the relationship between shear rate, von Willebrand factor (vWF) multimer integrity, and platelet aggregation.
  • To elucidate the mechanisms (mechanical shear vs. ADAMTS13) contributing to reduced platelet aggregation under shear stress.

Main Methods:

  • Human platelet-poor plasma with vWF and labeled platelets were subjected to shear rates from 0 to 10,000 s⁻¹ for up to 15 minutes using a custom blood-shearing device.
  • Platelet aggregate sizes were measured using microscopy.
  • High molecular weight (HMW) vWF multimers were quantified via gel electrophoresis and immunoblotting; inhibition studies explored mechanical and enzymatic effects.

Main Results:

  • Platelet aggregates were significantly larger at physiological shear rates (360–3000 s⁻¹) compared to high shear rates (>6000 s⁻¹).
  • Increased shear rates led to a reduction in HMW vWF multimers.
  • Inhibition studies indicated that ADAMTS13 was the primary mediator of reduced platelet aggregation size and HMW vWF multimer loss.

Conclusions:

  • Shear rates exceeding 6000 s⁻¹ significantly reduce platelet aggregate size, compromising their ability to form effective plugs.
  • Maintaining shear rates below this threshold is essential for preserving platelet function and preventing bleeding in LVAD patients.
  • ADAMTS13 plays a critical role in mitigating shear-induced platelet dysfunction and vWF degradation.